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Abstract  
Primary ciliary dyskinesia is a rare heterogeneous recessive genetic disorder of motile cilia, 
leading to chronic upper and lower respiratory symptoms. Prevalence is estimated at around 
1:10,000, but many patients remain undiagnosed, while others receive the label incorrectly. 
Proper diagnosis is complicated by the fact that the key symptoms such as wet cough, chronic 
rhinitis and recurrent upper and lower respiratory infection, are common and nonspecific. 
There is no single gold standard test to diagnose PCD. Presently, the diagnosis is made in 
patients with a compatible medical history following a demanding combination of tests 
including nasal nitric oxide, high-speed video microscopy, transmission electron microscopy, 
genetics, and ciliary culture. These tests are costly and need sophisticated equipment and 
experienced staff, restricting use to highly specialised centers. Therefore, it would be desirable 
to have a screening test for identifying those patients who should undergo detailed diagnostic 
testing. Three recent studies focused on potential screening tools:  one paper assessed the 
validity of nasal nitric oxide for screening, and two studies developed new symptom-based 
screening tools. These simple tools are welcome, and hopefully remind physicians whom to 
refer for definitive testing. However, they have been developed in tertiary care settings, where 
10 to 50% of tested patients have PCD. Sensitivity and specificity of the tools are reasonable, 
but positive and negative predictive values may be poor in primary or secondary care settings.  
While these studies take an important step forward towards an earlier diagnosis of PCD, more 
remains to be done before we have tools tailored to different health care settings.   
 
Abstract Word Count: 257 
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Primary ciliary dyskinesia (PCD) is an inherited disease characterized by abnormal ciliary 
function and, in about 80% of cases, abnormal ciliary ultrastructure (1, 2). It affects mucociliary 
clearance and leads to a wide variety of symptoms primarily affecting the respiratory system, 
which usually present soon after birth (3). The  key symptoms- -productive cough, chronic 
rhinitis and recurrent upper and lower respiratory tract infections--are all nonspecific and occur 
in many respiratory diseases, including common ones like asthma and COPD, and rare ones like 
cystic fibrosis and immune deficiency syndromes (4). Because embryonic nodal cilia determine 
left-right asymmetry, approximately half of PCD patients have situs inversus, and some have 
heterotaxic syndromes with or without cardiac malformations (5). Male infertility is common 
because sperm flagellae have a similar ultrastructure as cilia. Female infertility, renal 
malformations, hydrocephalus and retinitis pigmentosa are seen occasionally, but their 
incidence is unknown. 
 PCD is a rare disease. Its prevalence is difficult to determine because of limited 
representative data. Prevalence estimates for the general population vary between 1 in 2,000 
to 1 in 40,000. Prevalence estimates of 1 in 2,000 are derived from certain populations with 
high proportions of consanguineous marriages (6).  
Diagnosis of PCD is challenging. There is no single ‘gold standard’ diagnostic test. 
European Consensus guidelines (2009) recommend a combination of tests for symptomatic 
patients including measurement of nasal nitric oxide (nNO), high-speed video microscopy 
analysis (HSVMA) of ciliary beat frequency and pattern, and quantitative transmission electron 
microscopy (TEM) of ciliary ultrastructure(8). The European guidelines also suggest use of 
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additional tests such as immunofluorescence labelling of cilia proteins, pulmonary radioaerosol 
mucociliary clearance and genotyping.  
Recent North American Consensus guidelines (2016) are not dissimilar, but place more 
emphasis on genetic tests and less reliance on functional studies using  HSVMA (9). None of the 
available tests detects all patients with PCD. For instance, about 16%-20% of PCD patients have 
TEM without a detectable defect and some patients have a normal nNO (10, 11).   HSVMA is 
more sensitive, but not sufficiently standardised to rule out PCD as a stand-alone test (12). 
Reanalysis following submerged or air-liquid interface (ALI) culture helps to exclude secondary 
ciliary dyskinesia (13). More than 30 PCD-causing genes have been discovered, which together 
explain about 70% of PCD cases (14). 
In situations without a ‘gold standard’ diagnostic test, clinicians and researchers must 
determine diagnosis based on multiple test results (15, 16). The 3 diagnostic reference centers 
for PCD in England, work in close collaboration to diagnose PCD based on nNO, HSVMA and 
TEM (17, 18). Inconclusive and positive samples are reanalysed following culture. In North 
America, HSVM is not widely used, and PCD is diagnosed based on results from TEM, nNO and 
genetic testing (9, 16). All diagnostic tests for PCD are technically demanding, need up-to date 
equipment and well-trained staff with a high level of expertise. To allow technicians to acquire 
sufficient expertise with this rare disease, diagnostic facilities should be responsible for patient 
populations. For instance, in a region with a population of 1 million and an estimated 
prevalence of 1 in 10,000; we expect 100 persons to have PCD. Given the average life 
expectancy of 80 years, every year about 1 person will be newly diagnosed, if 100% of cases are 
diagnosed. In a region or country covering 10 million inhabitants, we expect a maximum of 10-
Page 4 of 17 ANNALSATS Articles in Press. Published on 03-June-2016 as 10.1513/AnnalsATS.201605-331PS 
 Copyright © 2016 by the American Thoracic Society 
  
12 new cases every year – this might be a minimal number to allow the diagnostic team to be 
familiar with positive TEM and HSVM findings, including difficult subtle cases.  
    
PCD is Underdiagnosed 
 
Although the estimated prevalence of PCD is around 1 in10,000 live births (19), a survey of 
paediatric pulmonologists from 26 European countries found that doctor-diagnosed cases were 
considerably less frequent in most countries and that half of the children were not diagnosed 
until school age. Diagnosis was particularly late in those with normal situs. Diagnostic testing 
and management of PCD was found to vary widely within Europe (20).  
In the U.S., fewer than 1000 patients had an established diagnosis of PCD in 2013, which 
would correspond to an incidence of approximately 1in 315,000. The median age at diagnosis 
was 5 years (21). A study from Australia reported a median age at diagnosis of 6.4 years, and 
disturbingly found bronchiectasis already present in one third (22).  
These studies did not take into consideration the larger adult population with ‘missed’ 
PCD. Delayed and overlooked diagnoses in North America, Europe and Australia shows that 
pediatricians are not thinking of this rare disease when encountering symptomatic patients. 
These findings are concerning because early detection and appropriate management might 
slow the progression of bronchiectasis, improve hearing to prevent speech and educational 
delays, and provide genetic counselling for families.  The problem extends to adult practice. 
Anecdotal evidence suggests that many adult patients are managed in non-CF bronchiectasis 
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clinics, where cystic fibrosis and immunological causes are excluded by appropriate diagnostic 
studies, but testing for PCD is often not considered.  
 
The Diagnostic Challenge 
 
What can we do to improve the situation, so that patients with PCD are diagnosed at a young 
age and receiving appropriate treatment? Given the low prevalence of the disease, and the high 
costs for testing, it is impossible to perform the whole set of diagnostic tests in the whole 
population or even in all patients with compatible symptoms. It would even be very costly to 
test 6 to 12 percent of the population for PCD, the proportion of children and young adults with 
chronic wet cough (23, 24).  Pulmonologists, neonatologists, otorhinolaryngologists, and 
pediatricians need guidance to identify patients whose complaints warrant extensive testing. 
Until now “clinical experience” was used to decide, which patients to refer for testing. The large 
proportion of undiagnosed PCD patients, and the reports from patients who were diagnosed 
after long delays, (7) shows that this strategy has not been very successful. A good screening 
test that filters out – among people with chronic respiratory symptoms – those most likely to 
have PCD, would be welcome.  
Three recent publications have focused on this topic, including one published in this 
issue of AnnalsATS (25) (Table 1). Collins et al investigated the validity of nNO as screening test 
for PCD in hypothetical populations with different prevalence of PCD (26). Reports by Behan 
and colleagues (27) and Leigh and coauthors (25) both propose screening tools based on 
symptom scores  
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Who Should be Referred for Diagnostic Testing? 
 
In a short paper, Collins and coworkers investigated the validity of nNO in the population of 282 
patients referred to one of the national PCD diagnostic centers in England. (26) Using a 
combination of tests, 11% of the referrals were finally diagnosed with PCD. Collins calculated 
sensitivity, specificity, positive and negative predictive values of nNO in this population, but also 
in hypothetical populations with a lower prevalence of PCD. He found that nNO performed well 
in his highly selected patients. However, in populations with a lower prevalence of PCD, the 
number of false positive cases identified by nNO would far out-weigh the true positives (26). If 
nNO was applied as a screening tool to the general population, it would lead to a huge number 
of patients wrongly referred to the expensive diagnostic services.   
Leigh and coauthors studied a cohort of patients aged 18 years of age or younger 
referred to one of 7 specialized medical centers participating in the North American Genetic 
Disorders of Mucociliary Clearance Consortium because of a high suspicion of PCD (25). They 
investigated the performance of 5 individual, pre-defined clinical characteristics and various 
combinations  these characteristics as predictors of PCD. They achieved this by comparing 
patients in whom PCD was confirmed by a hallmark ultrastructural defect or two mutations in a 
PCD-associated gene (‘definite PCD’, n=205) with patients, in whom PCD was excluded (‘other 
disease/undefined, n=187), or in whom PCD remained probable but could not be confirmed 
(‘probable PCD’, n=142).   
Among the 5 expert-defined symptoms, 4 were significantly more common in patients 
with definite PCD compared to ‘other/undefined’ patients. These were: neonatal respiratory 
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distress; chronic cough; chronic nasal congestion; and situs inversus. Recurrent otitis did not 
discriminate.  Rewording the symptoms to make them more specific (for instance ‘unexplained 
neonatal respiratory distress’ instead of ‘neonatal respiratory distress’) decreased prevalence 
of the feature in both groups, and thus decreased sensitivity but increased specificity of the 
symptoms compared to the more general wording. The authors calculated sensitivity and 
specificity for each symptom alone, and for combinations of two, 3, and 4 symptoms. The 
combination of laterality defects and neonatal distress performed best, with a sensitivity of 
34% and a specificity of 95%.    
Recently, Behan and coworkers proposed another symptom score as a predictive tool 
for PCD (27). They included 641 patients referred for diagnostic evaluation to the PCD 
Diagnostic Centre in University Hospital Southampton (UHS), of whom 75 (12%) were 
confirmed to have PCD.  The methodology differed from that employed by Leigh and 
colleagues. Rather than testing predefined predictors based on expert opinion, Behan and 
colleagues used a statistical approach to decide which of 27 questions recorded routinely 
during the PCD diagnostic clinic best predicted a diagnosis of PCD. Seven variables remained 
significantly associated with PCD in a multivariable logistic regression. As in the study by Leigh 
and colleagues, these included: situs inversus, neonatal chest symptoms, admission to the 
neonatal unit and rhinitis. 
 In contrast to Leigh’s study, chronic cough was not a predictor of PCD, being common in 
those with and without the diagnosis. However, gestational age, congenital heart defects, and 
ear and hearing problems were predictive.  The authors simplified the regression model into a 
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short clinical tool, which they call PICADAR (the PrImary CiliARy DyskinesiA Rule (27)). They then 
performed an external validation study on an independent cohort.  
The PICADAR score predicted with reasonable accuracy those who subsequently had a 
positive or negative test for PCD.  For example, using a cut-off score of 6, PICADAR had 89% 
sensitivity and 83% specificity to differentiate PCD positive and negative patients in the 
derivation group, and 81% sensitivity and 76% specificity in the validation group. If patients 
with a score of <6 had not proceeded to further testing, 247 (82.6%) and 59 (75.6%) negative 
patients would have avoided formal testing at the diagnostic centers however, it is important to 
caution that 8 (11.4%) positive patients in the derivation group and 15 (18.8%) in the validation 
group would have been missed. 
 
Extrapolation to Other Settings 
 
Can the results from these two studies be extrapolated to other settings, for instance other 
countries, other specialty practices, such as otorhinolaryngology clinics, or other levels of care 
(e.g. primary care)?  Only with great caution.  
All 3 screening tests perform reasonably well in the setting of highly specialised referral 
practices, where the studies had been conducted (Table 1). The PICADAR study came from a 
national diagnostic center for PCD in England; with most patients being referred via secondary 
or specialist respiratory care and 12% were finally diagnosed with PCD. The setting for the 
North American study was even more selective. Their study comprised a diagnostic re-
evaluation of a cohort of patients with a firm suspicion of PCD. Of 392 patients included in their 
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analysis, PCD was confirmed in 205 (52%), based on hallmark findings in transmission electron 
micrographs or the presence of two disease-causing mutations.   
The validity of the predictive symptom score in these studies is influenced by several 
factors: First, the mix of patients determined by local referral habits: this determines which 
predictors will discriminate between patients. Second, the definition of PCD (i.e. the diagnostic 
gold standard): this affects the sensitivity of the score. Third, the prevalence of PCD within the 
patient population: this influences positive and negative predictive value of test results.  
The first factor is illustrated nicely by the observation that chronic cough, a hallmark 
symptom of PCD, emerged as a significant predictor in the North American study but not in the 
UK study. This seeming paradox is explained by the fact, that chronic cough was a relative 
prerequisite for referral to the UK center and virtually every patient had it; thus cough did not 
discriminate between patients who finally were or were not diagnosed with PCD.  The PICADAR 
score therefore should only be applied to patients with chronic cough. In analogy, we would 
expect that in a study conducted in an otorhinolaryngology department, chronic rhinitis would 
not have emerged as a useful predictor.   
Secondly, as we lack a gold standard diagnostic test, both centers used a composite test 
for the final diagnosis. In PICADAR, this composite test included nNO, transmission electron 
microscopy, and HSVMA. In the US study, the diagnosis of PCD was based on hallmark findings 
on transmission electron microscopy or the presence of two disease-specific mutations. As PCD 
genes currently explain only 70% of PCD cases, and a significant proportion of patients have 
normal ciliary ultrastructure on transmission electron microscopy, this approach misses 
patients who therefore landed in the “probable/possible” category. Adding these cases in a 
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sensitivity analysis did reduce sensitivity of the prognostic score, as illustrated in online table 1 
in (25).  
Thirdly, while sensitivity and specificity are independent of the prevalence of the 
disease, the positive and negative predictive values are strongly influenced by the prevalence of 
PCD among those referred for testing. For example, the combination of laterality defects and a 
history of neonatal distress had, in the US cohort (PCD prevalence of 52%), a sensitivity of 34% 
and a specificity of 95%. This translates into a positive predictive value of 88% and a negative 
predicted value of 57% (Table 1, Scenario 1).  
In a cohort where only 12% of the referral group has PCD, as in the UK study, the 
positive and negative predictive values change to 48% and 91% respectively (Table 1, Scenario 
2). If only 1 in 100 patients have PCD, as might be the case in respiratory patients seen in 
secondary care (Table 1, Scenario 3), or 1 in 10,000, as in the general population  (Table 1, 
Scenario 4), the positive predictive value would fall to 6% and 0.07% respectively. The same can 
be observed for the PICADAR tool and nNO: the positive predictive value, e.g. the likelihood 
that a positively screened patient has PCD, falls with decreasing prevalence of PCD in the study 
population.  
As is the case with cystic fibrosis, there are mild or atypical phenotypes of inherited ciliary 
dysfunction, many of which have not yet been fully characterized. Some may manifest later in 
childhood or first in adults.  A limitation of studies investigating diagnostic and screening tests 
for PCD is that they systematically exclude patients with atypical symptoms because the 
diagnosis has not been considered. For example, patients with defects effecting the central 
apparatus of the cilia will not have situs abnormalities and are thereby systematically less likely 
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to score highly on either of the symptom screening tools. Similarly there are a small number of 
patients whose PCD is caused by mutations associated with normal nasal nitric oxide levels. 
Adults might often not know about neonatal symptoms, or at least not report them proactively, 
which again decreases their scores in both instruments. Furthermore, ‘atypical’ patients might 
be falsely labelled as ‘PCD negative’ by detailed diagnostic testing because current diagnostic 
tests (e.g. TEM and genetics) fail to identify them correctly.  
 
Conclusions 
 
In summary, two recent studies have developed symptom-based tools that can be used to 
identify patients at high risk for primary ciliary dyskinesia. Both are welcomed as they will raise 
awareness of the symptoms of PCD amongst non-specialists. Before they are put into 
widespread use, the tools require validation in different clinical settings, for instance, primary, 
secondary and tertiary care, in pediatric pulmonology, adult pulmonology, or 
otorhinolaryngology. We can then refine and adapt the prediction tools for these settings. 
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Table 1: Relationship between PPV and NPV and the pretest probability of PCD (proportion of patients with PCD in the tested population), for 
three proposed screening tests for PCD: nasal NO, PICADAR (cut-off >6), and clinical symptom score (combination of neonatal distress and 
laterality defects. 
 
Publicati
on 
Screening 
instrument 
  Scenario 1 
US referral group 
PCD prevalence = 
52% 
Scenario 2 
UK referral group 
PCD prevalence = 
12% 
Scenario 3 
Secondary care 
PCD prevalence = 1% 
Scenario 4 
General population 
PCD 
prevalence=0.01% 
  Sensitivit
y 
Specificit
y 
PPV NPV PPV NPV PPV NPV PPV NPV 
Collins et 
al (26) 
nNO (cut-off 
77nl/min) 
94% 84% 86% 92% 44% 99% 6% 99.9% 0.06% 99.9% 
Behan et 
al (27) 
PICADAR tool 
(cut-off score >6) 
76% 94% 93% 78% 63% 97% 11% 99.7% 0.1% 99.9% 
Leigh et 
al (25) 
Symptoms score 
(neonatal distress 
& laterality 
defects) 
34% 95% 88% 57% 48% 91% 6% 99.3% 0.07% 99.9% 
 
Legend: PPV: positive predictive value; NPV negative predictive value. Sensitivity and specificity do not vary with disease prevalence. Columns 
represent four different scenarios: 1) 52% of patients have PCD, as in (25); 2) 12% of patients have PCD as in (27); 3) 1% of patients has PCD as 
in patients with chronic respiratory symptoms presenting to secondary care; 4) 0.01% of patients have PCD as in the general population. 
 
 
 
Page 17 of 17  ANNALSATS Articles in Press. Published on 03-June-2016 as 10.1513/AnnalsATS.201605-331PS 
 Copyright © 2016 by the American Thoracic Society 
